pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioPharma Dive·Aug 27·1 min read
save

Outer Bio unveils skin‑tissue platform that keeps samples alive for a month, creating terabytes of data for skincare research

Aug 27, 2026·read at BioPharma Dive ↗Positive

Outer Bio, a new biotech founded by Michael Polansky, has emerged from stealth to offer a skin‑focused platform that maintains harvested human skin tissue alive for about a month.

The company says the tissue retains its structure and resident immune cells, unlike typical samples that degrade within a week, allowing more realistic studies of inflammation and injury responses.

Using artificial‑intelligence tools to screen millions of compounds, Outer Bio pairs each compound with the long‑living tissue, producing over 30,000 data points per pairing and has already generated more than 10 terabytes of data from over 300 donors and 10,000 potential treatments.

While the platform is positioned for skincare ingredient discovery, the company notes the data could also be valuable for pharmaceutical research into skin conditions.

source

This writeup was produced by pharmadog from original reporting by BioPharma Dive.

Original headline: “Michael Polansky has a new, skin-focused biotech. Don’t call it a drug company.”

read at BioPharma Dive ↗
2,373 words · retrieved Aug 27
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
PATH4
topics
Dermatology18Immunology2Oncology2Ophthalmology2

related stories

  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • 9h agoCaribou layoffs could wipe out 90% of staffBioSpace
  • Sep 29ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’BioPharma Dive
  • Sep 286 immunology targets to sustain a mammoth I&I marketBioSpace
  • Sep 17Roche, Dualitas team up to find bispecific drugs for immune diseasesBioPharma Dive